Dimethyl fumarate (DMF) is an electrophilic drug that is used to treat autoimmune conditions, including multiple sclerosis and psoriasis. The mechanism of action of DMF is unclear but may involve the covalent modification of proteins or DMF serving as a prodrug that is converted to monomethyl fumarate (MMF). We found that DMF, but not MMF, blocked the activation of primary human and mouse T cells. Using a quantitative, site-specific chemical proteomic platform, we determined the DMF sensitivity of >2400 cysteine residues in human T cells. Cysteines sensitive to DMF, but not MMF, were identified in several proteins with established biochemical or genetic links to T cell function, including protein kinase Cq (PKCq). DMF blocked the association of PKCq with the costimulatory receptor CD28 by perturbing a CXXC motif in the C2 domain of this kinase. Mutation of these DMF-sensitive cysteines also impaired PKCq-CD28 interactions and T cell activation, designating the C2 domain of PKCq as a key functional, electrophile-sensing module important for T cell biology.
INTRODUCTION
Fumaric acid esters, including dimethyl fumarate (DMF), were first used in the treatment of autoimmunity over half a century ago. In 1959, a German biochemist suffering from psoriasis self-administered fumaric acid esters, believing his skin condition to be a result of a fumarate deficiency (1) . In the 1990s, a mixture of DMF and other fumarates (together known as Fumaderm) was shown to exhibit positive activity in clinical trials for psoriasis. Two multiple sclerosis (MS) patients who had been taking Fumaderm for their psoriasis noted that their MS symptoms also stabilized while on the drug. This motivated the clinical investigation of DMF for MS (2) (3) (4) , and in 2013, the compound was approved by the U.S. Food and Drug Administration as an oral therapy for MS, which is now sold under the trade name Tecfidera (5) .
Despite its success in the clinic, the mechanism of action of DMF remains poorly understood. DMF is an electrophilic drug with the potential to react through its Michael acceptor unit with cysteine residues in proteins. Several groups have therefore posited that the drug stimulates an antioxidant response by modifying cysteine residues in the Nrf2 (nuclear factor erythroid 2-related factor 2)-Keap1 (Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1) complex, a major electrophile response pathway in mammalian cells (6, 7) . Keap1 is a cysteine-rich protein that promotes the proteasomal degradation of Nrf2. Electrophilic or oxidative modification of one or more cysteines in Keap1 causes its disassociation from Nrf2, enabling this transcription factor to bind to antioxidant response elements in DNA and regulate gene expression (6) . Others have suggested that DMF acts through the alteration of cellular glutathione (GSH) concentrations, thereby perturbing redox homeostasis (8) (9) (10) (11) . Alternative models for DMF action have also been put forth, including its ability to serve as a prodrug for the hydrolyzed product monomethyl fumarate (MMF), which acts as a ligand for the G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor hydroxycarboxylic acid receptor 2 (12) .
In addition to displaying neuroprotective activity (7, 9) , DMF exhibits immunomodulatory properties, including reducing the production of the cytokines interleukin-2 (IL-2), IL-6, and IL-17 by murine splenocyte cultures (9, 13) , as well as the production of IL-12 and IL-23 by both mouse and human dendritic cells (14) . Reductions in the numbers of CD4 + T cells that express the inflammatory cytokine interferon-g have also been observed in humans taking DMF (14) . At least some of the immunosuppressive effects of DMF occur independently of Nrf2 modulation (15) and are not observed with MMF (13) , pointing to different proteins and pathways as sites of action for DMF in immune cells. DMF suppresses nuclear factor kB (NF-kB) signaling in different cell types (13, (16) (17) (18) (19) , which is one potential pathway for immunoregulation, although the mechanism by which this occurs remains ill-defined. These findings, combined with the efficacy of DMF in treating both MS and psoriasis, as well as the emergence of rare but life-threatening cases of progressive multifocal leukoencephalopathy (PML) among patients taking DMF (20) , underscore the importance of elucidating the molecular basis for its immunosuppressive activity.
Our group introduced a chemical proteomic method for quantitatively profiling the reactivity of cysteine residues directly in native cells and tissues (21, 22) . Here, we applied this method, termed isoTOP-ABPP (isotopic tandem orthogonal proteolysis-activity-based protein profiling), to quantify the reactivity of DMF with >2400 cysteine residues across~1500 proteins in primary human and mouse T lymphocytes. We discovered numerous cysteine residues that were sensitive to DMF at concentrations where this drug, but not unreactive structural analogs, suppresses T cell activation. Several proteins harboring DMF-sensitive cysteine residues have established immune regulatory functions. We performed follow-up studies on protein kinase Cq (PKCq) and showed that a DMF-sensitive CXXC motif located within its N-terminal C2 domain is critical for interactions with the costimulatory receptor CD28 and for T cell activation.
release from mouse splenocytes (9) and promotes a T helper 2 (T H 2)-type phenotype by causing an increase in IL-10 secretion from human and mouse dendritic cells (14) . We first tested the effects of DMF and MMF (Fig. 1A) on cytokine release from total primary human T cells activated with anti-CD3 and anti-CD28 (anti-CD3/CD28) antibodies. Secretion of IL-2 was substantially inhibited by DMF, but not MMF or the nonelectrophilic analog dimethyl succinate (DMS; Fig. 1, A and B) . DMF, but not MMF or DMS, also substantially blocked the cell surface expression of the early activation markers CD25 (Fig. 1, C and D) and CD69 (Fig. 1E ) in anti-CD3/ CD28-stimulated T cells. The blockade of T cell activation by DMF was concentration-dependent, with the drug producing marginal, partial, and nearcomplete inhibition at concentrations of 10, 25, and 50 mM, respectively (Fig. 1,  B to E). Furthermore, the effects of DMF on cytokine release and activation markers occurred at concentrations of the drug that did not impair T cell viability ( fig. S1 ). Similar results were obtained with primary splenic T cells from C57BL/6 mice, the activation of which was also suppressed by DMF, but not MMF or DMS ( fig. S2 ). DMF caused marked inhibition of human T cell activation even when treatment was limited to the first 2 hours of activation (Fig. 1F) , suggesting that DMF inhibits an early event(s) in the T cell activation pathway.
The effects of DMF on T cell activation are independent of Nrf2 and GSH DMF is thought to produce neuroprotective effects by activating the Nrf2-Keap1 pathway (6, 7), but whether this pathway contributes to the immunomodulatory effects of DMF is unclear. A study showed that DMF inhibits the release of proinflammatory cytokines from primary mouse splenocytes and that this effect is comparable in wild-type (WT) and Nrf2 −/− splenocytes (13). Consistent with this work, we found that the activation of Nrf2 +/+ and Nrf2
−/−
T cells was similarly sensitive to inhibition by DMF ( Fig. 2A) . DMF might also impair T cell activation by depleting GSH, and DMF-treated primary human T cells showed a substantial decrease in cellular GSH content (Fig. 2B ). Marked reductions in GSH were, however, also observed with the GSH synthesis inhibitor buthionine sulfoximine (BSO), which had no effect on T cell activation (Fig. 2, C and D) . These data suggest that the blockade of T cell activation by DMF involves processes other than Nrf2 activation or GSH depletion.
Chemical proteomics reveals DMF-sensitive cysteine residues in T cells
The inhibition of T cell activation by DMF, but not the nonelectrophilic analogs MMF and DMS, pointed to a mechanism involving covalent reactivity with one or more proteins important for T cell function. Therefore, we next sought to identify DMF-sensitive cysteine residues in primary human and mouse T cells with the quantitative chemical proteomic platform isoTOP-ABPP (21, 22) . In this method, DMF was evaluated for its ability to block the reactivity of proteinaceous cysteine residues with the general electrophilic probe iodoacetamide-alkyne (IA-alkyne).
Using isotopically differentiated azide-biotin tags [containing a tobacco etch virus (TEV) protease-cleavable linker], we identified cysteine residues and comparatively quantified their IA reactivity in cells treated with DMF versus DMSO control. The primary advantages of the isoTOP-ABPP platform are as follows: (i) the competing electrophile does not itself need to be chemically altered for target identification, which is particularly beneficial when to six technical replicates from each of two experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed, unpaired t test in comparison to the DMSO-treated cells.
studying very small compounds like DMF, and (ii) isotopic labeling occurs late in the sample processing, which facilitates the quantitative analysis of primary cells and tissues that are not readily amenable to metabolic labeling. We performed isoTOP-ABPP on primary human T cells stimulated with anti-CD3/CD28 antibodies and treated with DMSO or 50 mM DMF for 4 hours. Five independent replicate experiments were performed, and the total aggregate number of unique quantified peptides and proteins began to plateau by the fourth and fifth replicates ( fig. S3 ), indicating that we had approached the maximal proteomic coverage of IA-reactive cysteine residues in human T cells that is achievable with the isoTOP-ABPP method under the conditions used. Of more than 2400 quantified cysteine residues, a small fraction (~40) showed substantial reductions [>4-fold; isoTOP-ABPP ratio (R) > 4] in IA-alkyne labeling in DMF-treated T cells (Fig. 3A, table S1 , and data file S1). Similar isoTOP-ABPP analyses revealed that none of the~40 DMF-sensitive cysteine residues were altered by treatment with 50 mM MMF or 2.5 mM BSO for 4 hours, which, in general, affected the reactivity of very few cysteine residues across the T cell proteome (Fig. 3, A and B,  and fig. S4 ).
The cysteine residues targeted by DMF exhibited concentrationdependent ( Fig. 3C and data file S1) and time-dependent ( Fig. 3D and data file S1) increases in DMF sensitivity, as revealed by isoTOP-ABPP experiments performed with human T cells that were treated with lower concentrations of DMF (10 and 25 mM for 4 hours; Fig. 3C ) or for shorter periods of time (50 mM DMF for 1 or 2 hours; Fig. 3D ). Very few DMF-sensitive cysteine residues were detected in T cells treated with 10 mM DMF (Fig. 3C) , a concentration of the drug that also had a limited effect on T cell activation (Fig. 1, B to E) . These concentration-and time-dependent studies uncovered another~10 DMF-sensitive cysteine residues that were not detected in the original isoTOP-ABPP experiments (50 mM DMF for 4 hours), likely reflecting the stochastic nature of peptide discovery in data-dependent MS experiments.
We considered the possibility that some of the alterations in cysteine reactivity after treatment with DMF might reflect changes in protein abundance; however, multiple cysteine residues were quantified by isoTOP-ABPP for most of the proteins harboring DMF-sensitive cysteine residues, and in most of these cases, the additional quantified cysteine residues were unaffected by DMF (Fig. 3E) . The DNA-dependent protein kinase catalytic subunit PRKDC is one representative example for which IA-alkyne reactivity was quantified for several cysteine residues, only one of which (Cys 4045 ) was blocked by DMF (Fig. 3F) . These results suggest that DMF directly impairs the IA-alkyne reactivity of specific cysteine residues, rather than indirectly affecting protein abundance in human T cells.
DMF-sensitive cysteine residues are conserved in mice
Considering that DMF impaired the activation of both human and mouse T cells, we surmised that at least a subset of the cysteine residues potentially important for mediating the action of DMF might be conserved in humans and mice. Consistent with this hypothesis, we found that about two-thirds of the DMF-sensitive cysteine residues discovered in human T cells are conserved in mice ( Fig. 4A and table S1 ). We next performed isoTOP-ABPP experiments on mouse T cells stimulated with anti-CD3/CD28 antibodies and treated with 50 mM DMF for 4 hours. We found that most (>80%) of the conserved, quantified cysteine residues that were sensitive to DMF in activated human T cells were also blocked (R > 4) by this drug in activated mouse T cells ( Fig. 4B and data file S1). These results suggest that DMF targets a similar array of cysteine residues in human and mouse T cells, pointing to a specific set of proteins as the candidate sites of action for this electrophilic drug.
The proteins containing DMF-sensitive cysteine residues, as a whole, originated from several functional classes, including enzymes, channels, transporters, scaffolding proteins, and transcriptional regulators (Fig. 4C ). Among these proteins were several with important immune functions (table S1). DMF-sensitive cysteine residues were found, for example, in multiple proteins that are either components or regulators of the NF-kB signaling pathway, including inhibitor of kB kinase b (IKKb or IKBKB) (24), PKCq (or PRKCQ) (25, 26) , and tumor necrosis factor-a-induced protein 3 (TNFAIP3; also known as A20) (table S1) (27, 28) . Consistent with these, and potentially other, sites of DMF action being within the NF-kB pathway (19), we found that DMF blocked the nuclear translocation of p65 in anti-CD3/CD28-stimulated human T cells ( fig. S5 ), as has been shown in other cell types (13, (16) (17) (18) (19) . DMF-sensitive cysteine residues were also found in the following: (i) the adenosine deaminase enzyme ADA, deleterious mutations in which cause severe combined immunodeficiency in humans (29) Primary human T cells were left unstimulated or were stimulated with anti-CD3/CD28 antibodies in the presence of DMSO, 50 mM DMF, or 2.5 mM BSO for 8 hours. The cells were then analyzed by flow cytometry to measure the cell surface abundance of CD25. Data are means ± SEM of three or four technical replicates from each of two experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed, unpaired t test in comparison to the DMSO-treated cells. S1). Given its crucial role in early T cell activation, we focused our attention on PKCq as a case study to begin to understand how DMF affects the function of immunologically relevant proteins in T cells.
DMF perturbs a functional CXXC motif in the C2 domain of PKCq
PKCq is a key kinase involved in T cell signaling at the immunological synapse, where engagement of the T cell receptor (TCR) and the costimulatory receptor CD28 initiates the activation of multiple downstream pathways, including NF-kB (25, 26) . T cells from PKCq −/− mice are defective in early activation (30, 31) . The isoTOP-ABPP analysis identified two DMF-sensitive cysteine residues in PKCq, Cys 14 and Cys . S6D ). Because Cys 14 and Cys 17 are found on the same tryptic peptide, it was difficult to distinguish whether one or both residues were sensitive to DMF. However, in certain isoTOP-ABPP experiments, this tryptic peptide appeared to migrate as two adjacent peaks, both of which showed DMF sensitivity ( Fig. 5A) , suggesting that the IA-alkyne reactivity of both Cys 14 and Cys 17 is blocked by DMF. The isoTOP-ABPP experiments also identified a third cysteine in PKCq (Cys 322 ) that was unaffected by DMF (Fig. 5A ), indicating that DMF caused reductions in the reactivity of Cys 14 and Cys 17 rather than changes in PKCq abundance. Cys 14 and Cys 17 form a CXXC motif found in the C2 domain of PKCq, but not other PKC isoforms (Fig. 5, B and C) . The C2 domain of PKCq binds to phosphotyrosine-containing peptides (32) and is postulated to stabilize the plasma membrane association of PKCq at the immunological synapse (33) . Upon stimulation of TCR and CD28, PKCq is recruited to the immunological synapse where it interacts with CD28 by associating with its cytoplasmic tail (34, 35) . We found that DMF, but not MMF, blocked the interaction between PKCq and CD28 in mouse T cells (Fig. 5D and fig. S7A ). We next used retroviral transduction to reconstitute PKCq −/− mouse T cells with either WT PKCq or a C14S-C17S double mutant PKCq and found that the mutant protein failed to associate with CD28 ( Fig. 5E and fig. S7B ). PKCq −/− T cells reconstituted with the C14S-C17S mutant PKCq also showed impaired cell surface expression of CD25 (Fig. 5F ) and IL-2 release (Fig. 5G ) in response to anti-CD3/CD28 antibodies compared to similarly stimulated cells reconstituted with WT PKCq. DMF further reduced the already impaired ability of PKCq −/− T cells reconstituted with the C14S-C17S mutant PKCq to produce IL-2 ( Fig. 5H) , indicating that the full inhibitory activity of DMF involves proteins in addition to PKCq. Combined with previous findings showing that the induced association between PKCq and CD28 is critical for localizing PKCq to the center of the immunological synapse (36), our results designate Cys 14 
/Cys
17 within the C2 domain of PKCq as a motif that regulates protein-protein interactions that are important for establishing kinase signaling complexes in immune cells. Moreover, disruption of this motif by DMF or genetic mutation impairs T cell activation.
DISCUSSION
Considering that DMF is efficacious in two distinct autoimmune conditionspsoriasis and MS-it is reasonable to speculate that the mechanism of action of the drug has a strong immunomodulatory component. The death of a patient in October 2014 due to PML (20) supports this hypothesis; PML is a rare, but serious, viral infection seen almost exclusively in immunocompromised individuals. Consistent with previous studies (13), we showed here that DMF, but not its main metabolite MMF, inhibited the activation of primary human T cells. The inhibitory activity of DMF was also observed in mouse T cells, including T cells from Nrf2 −/− animals, but was not displayed by the unreactive analog DMS or by BSO, a pharmacological agent that reduces the amount of GSH in T cells. These results point to a mechanism of action for DMF that involves covalent reaction with proteinaceous cysteine residues in the T cell proteome.
The chemical proteomic method isoTOP-ABPP, by evaluating electrophilic compounds for the blockade of IA reactivity across thousands of cysteine residues in parallel, provided a global way to discover DMF-sensitive cysteine residues in T cells without requiring any chemical modification to DMF itself. The aggregate number of DMF-sensitive cysteine residues accounted for~1% of the total cysteine residues quantified in human T cell proteomes, which is a similar degree of proteomic reactivity to that displayed by endogenous lipid electrophiles, such as 4-hydroxy-2-nonenal, which has been also evaluated by isoTOP-ABPP (21) . Almost all of the cysteine residues targeted by DMF in T cells showed sensitivity across a concentration range mirroring the range that suppressed T cell activation, with both parameters increasing between 10 and 50 mM (for example, compare Fig. 1, C to E, and Fig. 3C) . None of the DMF-sensitive cysteine residues in T cells were affected by MMF, which is consistent with previous work showing that DMF reacts much more rapidly with GSH than does MMF (36) . These data provide evidence that the reactivity of DMF with cysteine residues is mechanistically relevant to the immunosuppressive activity of the drug.
A substantial number of the proteins harboring DMF-sensitive cysteine residues have established roles in immunology. In the case of PKCq, which participates in signal transduction pathways that promote T cell activation, we discovered that the DMF-sensitive cysteine residues are important for the TCR-induced association between PKCq and CD28, which, in turn, localize this kinase to the immunological synapse (36) . The fact that these cysteine residues are found in the C2 domain of PKCq suggests a potentially druggable, non-active site position on this kinase for generating immunosuppressive therapies. Notably, other PKC isoforms, including the closely related PKCd and PKCe, do not have the CXXC motif found in PKCq (Fig. 5B) , indicating that the action of DMF is likely restricted to PKCq over other PKC family members. Moreover, PKCq-deficient mice are resistant to experimental autoimmune encephalomyelitis (37) , which suggests that PKCq-selective inhibitors could have efficacy in MS. Although our data support the idea that disruption of PKCq function is an important component of DMF action, the ability of DMF to further reduce IL-2 secretion from PKCq −/− T cells (Fig. 5H) indicates that DMF acts through multiple targets to produce its full inhibitory effect in T cells. These findings point to the potential for covalent drugs to produce biologically important effects through polypharmacology rather than by acting on single targets in cells.
Whether, and how, DMF affects the function of other immunologically relevant protein targets is not yet clear, but we can offer some speculation. For ADA, the DMF-sensitive cysteine residue Cys 75 is located between two amino acids, Gly 74 and Arg
76
, which, when mutated in humans, contribute to an immunosuppressive phenotype (38) . The region of ADA formed by amino acid residues 74 to 76 is more than 25 Å from the active site of the enzyme ( fig. S8 ), suggesting that it performs a noncatalytic function that is possibly perturbed by DMF reactivity. The DMF-sensitive cysteine in IKKb is located in the leucine-zipper domain and is distinct from another electrophilesensitive cysteine residue, Cys 179 (39) , which is found in the active site of this kinase. We should note that Cys 179 was not detected in our isoTOP-ABPP experiments, so we cannot conclude whether this cysteine residue is also sensitive to DMF.
Looking forward, it would be interesting to apply the chemical proteomic approach described herein to other cell types to expand our knowledge of DMF action. Discovery of DMF-sensitive cysteine residues in primary neurons, for example, could help to explain the neuroprotective effects of the drug. The isoTOP-ABPP platform could also be used to investigate other cysteine-targeting drugs of ill-defined mechanism, many of which display immunomodulatory activity, for example, curcumin (40) and bardoxolone (41) (42) (43) , among others. We should also discuss some of the limitations of the isoTOP-ABPP method. Because isoTOP-ABPP quantifies the reduction in the IA-alkyne reactivity of cysteine residues in the presence of a competing small-molecule electrophile, the method provides robust estimates of high-stoichiometry electrophile-cysteine interactions. On the other hand, low-stoichiometry electrophile-cysteine interactions (<50% engagement) are more difficult to measure with accuracy. This shortcoming means that isoTOP-ABPP may be better poised to identify electrophile-cysteine interactions that impair, rather than stimulate, protein function, because activating interactions could occur at low stoichiometry. The isoTOP-ABPP method may fail to detect electrophile-sensitive cysteine residues that are found on nonproteotypic peptides, for example, very small, large, or hydrophobic tryptic peptides, or those peptides that exhibit poor reactivity with the IA-alkyne probe. Finally, although our data suggest that the effects of DMF on T cell activation occur through covalent reactivity, it is possible, and even likely, that the remarkable efficacy displayed by this drug in vivo reflects a multitude of mechanisms, some of which may involve noncovalent interactions of DMF or MMF with proteins that would not be detected by isoTOP-ABPP.
In conclusion, we believe that the chemical proteomic resource reported herein, by revealing not only the proteins but also the specific cysteine residues on these proteins that are targeted by DMF in primary T cells, provides a strong foundation for mechanistic understanding of the pharmacological activities of this immunosuppressive drug. Those cysteine residues, like 17 in PKCq, that are found to affect T cell function upon modification by DMF may serve as focal points for future medicinal chemistry efforts aimed at generating covalent ligands with improved potency and selectivity. In this regard, a substantial fraction (~75%) of the DMF-sensitive cysteine residues discovered herein were also identified as targets of structurally distinct fragment electrophiles in a recent isoTOP-ABPP analysis of more than 5000 cysteine residues in human cancer cell line proteomes (44) . These fragment electrophiles may thus offer launching points for the development of next-generation immunosuppressive probes and drugs.
MATERIALS AND METHODS

Chemical reagents
Assays were performed with the following reagents: DMF (242926, Sigma-Aldrich), MMF (651419, Sigma-Aldrich), DMS (W239607, Sigma-Aldrich), and BSO (14484, Cayman Chemical).
Isolation of primary human T cells
All studies with samples from human volunteers followed protocols approved by the The Scripps Research Institute Institutional Review Board. Blood from healthy donors (females aged 30 to 49) were obtained after informed consent. Peripheral blood mononuclear cells (PBMCs) were purified over Histopaque-1077 gradients (10771, Sigma) according to the manufacturer's instructions. Briefly, blood (20-× 25-ml aliquots) was layered over Histopaque-1077 (12.5 ml), and the samples were then fractionated by centrifugation at 750g for 20 min at 20°C with no brake. PBMCs were harvested from the Histopaque-plasma interface and washed twice with phosphate-buffered saline (PBS). After that time, T cells were isolated with EasySep Human T Cell Isolation Kit (17951, STEMCELL Technologies) according to the manufacturer's instructions.
Mice
C57BL/6J and Nrf2
−/− mice (stock no. 017009, Nfe2l2 tm1Ywk , the Jackson Laboratory) were bred and maintained in a closed breeding facility at The Scripps Research Institute and were 6 to 8 weeks old when used in the experiments. All mice were used in accordance with the guidelines from the Institutional Animal Care and Use Committee of The Scripps Research Institute. For preactivated with plate-coated anti-CD3/CD28 antibodies for 24 hours before undergoing retroviral transduction. The cells were rested in culture medium without stimulation for 48 hours and then were incubated with or without plate-coated anti-CD3/CD28 antibodies (1 mg/ml) overnight (F) or for 48 hours (G and H), or with soluble anti-CD3/CD28 antibodies (10 mg/ml) for 5 min before being subjected to immunoprecipitation (E). Data in (F) to (H) are means ± SEM of three biological replicates. *P < 0.05, **P < 0.01, and ***P < 0.001 by two-tailed, unpaired t test.
the PKCq studies, C57BL/6 mice and Prkcq −/− mice (a gift from D. Littman) were housed under specific pathogen-free conditions and used in accordance with a protocol approved by the La Jolla Institute for Allergy and Immunology Animal Care Committee.
Isolation of primary mouse T cells
Spleens were harvested from female mice, perfused with collagenase, and incubated at 37°C with 5% CO 2 for 30 min. After this time, the spleens were homogenized. Cells that passed through a 100-mm cell strainer were collected and washed with RPMI. T cells were isolated from the splenocytes with the EasySep Mouse T cell Isolation Kit (19851, STEMCELLTechnologies) according to the manufacturer's instructions. For the PKCq studies, CD4 + T cells were isolated by anti-mouse CD4 magnetic particles (L3T4, BD IMag) and were cultured in RPMI 1640 medium (Gibco) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 1 mM non-essential amino acids for minimum essential medium penicillin G and streptomycin (each at 100 U/ml; Life Technologies), and recombinant IL-2 (100 U/ml; BioLegend).
T cell stimulation
Plates with 96 wells were coated with anti-CD3 (1:200; Bio X Cell) and anti-CD28 (1:500; 302933, BioLegend) antibodies in PBS (100 ml per well) overnight at 4°C. The plates were then washed twice with PBS, and to each well, 500,000 primary T cells in 100 ml of RPMI supplemented with 10% FBS, glutamine, and penicillin-streptomycin were added. Cells were then treated with 100 ml of medium containing the appropriate compounds at the concentrations indicated in the figure legends (with a final volume of 200 ml per well). Cells were kept at 37°C in a 5% CO 2 incubator for the times indicated in the figure legends and were harvested by centrifugation at 500g for 8 min at 4°C, which was followed by washing with PBS.
Cellular analysis and sorting by flow cytometry
Cells were transferred to a round-bottom, 96-well plate (0720095, Fisher Scientific), harvested by centrifugation at 500g for 3 min at 4°C, washed with PBS, and stained with LIVE/DEAD fixable cell stain (L23105, Thermo Fisher) according to the manufacturer's instructions. Briefly, one vial of LIVE/ DEAD stain was resuspended in 50 ml of DMSO and added to 20 ml of PBS. The diluted stain (200 ml) was added to each well of the 96-well plate, and the cells were incubated on ice for 30 min in the dark. After this time, the cells were pelleted and washed once with PBS, and then were incubated with antibodies specific for the appropriate cell surface markers. Flow cytometric analysis of cell surface markers was performed with the following antibodies: Pacific Blue-conjugated anti-CD8 (1:200 dilution; clone RPA-T8, BD Biosciences), allophycocyanin-conjugated anti-CD4 (1:200 dilution; clone RPA-T4, eBioscience), phycoerythrin-conjugated anti-CD25 [1:200 dilution; clone BC96, eBioscience; or PC61, BioLegend (for PKCq studies)], and fluorescein isothiocyanate-conjugated anti-CD69 (1:200 dilution; clone FN50, eBioscience). All antibodies were diluted in PBS with 1% FBS, and 50 ml was added to each well. Cells were incubated for 15 min on ice in the dark, after which the cells were harvested by centrifugation at 500g for 3 min at 4°C, washed with PBS with 1% FBS, and resuspended in 200 ml per well of PBS with 4% paraformaldehyde (PFA). Acquisition of flow cytometry data was performed with a BD FACSDiva-driven BD LSR II Flow Cytometer ) were stimulated for 48 hours with anti-CD3 antibody alone or together with anti-CD28 antibody, and the concentration of IL-2 in the culture medium was determined by ELISA according to the manufacturer's instructions (BioLegend). Briefly, a 96-well plate (Corning Costar) was coated overnight at 4°C with anti-IL-2 monoclonal antibody. Triplicates of IL-2 standards and medium from cultured cells were then added to the plate, which was followed by a 2-hour incubation at room temperature. A biotinylated polyclonal antibody against IL-2 was added to the plate, which was followed by incubation for 1 hour at room temperature, and then horseradish peroxidase (HRP)-conjugated avidin (avidin-HRP) was added, followed by incubation for 30 min at room temperature. The amount of bound avidin was then assessed with 3,3′,5,5′-tetramethylbenzidine peroxidase that was acidified by 2 N H 2 SO 4 . The absorbance of each well at 450 nm was then measured with a spectrophotometric plate reader (BioTek).
Quantification of cellular GSH concentrations
Primary human T cells (2.5 × 10 6 cells/ml, 20 ml per condition) were treated as indicated in the figure legends, harvested by centrifugation at 500g for 8 min at 4°C, and washed twice with PBS. Lysis buffer (75 ml) was added to the cell pellet (CS1020, Sigma-Aldrich). After being mixed by vortex, the samples were incubated on ice for 15 min and then harvested by centrifugation at 16,000g for 10 min at 4°C. Protein concentrations were adjusted to at least 5 mg/ml, and the assay was performed according to the manufacturer's instructions (CS1020, Sigma-Aldrich). Data are means ± SEM for three or four technical replicates from each of the two biological replicates.
Protein labeling and click chemistry
T cells were stimulated and treated in 96-well plates as described earlier. Cells were harvested, lysed by sonication, and diluted to a concentration of 2 mg protein/ml. Protein concentrations were measured with the Bio-Rad DC protein assay reagents A and B (5000113 and 5000114, Bio-Rad). Proteome sample (500 ml) was treated with 100 mM IA-alkyne probe by adding 5 ml of a 10 mM probe stock (in DMSO). The labeling reactions were incubated at room temperature for 1 hour, after which the samples were conjugated to isotopically labeled, TEV-cleavable tags (TEV tags) by coppercatalyzed azide-alkyne cycloaddition (CuACC or "click chemistry"). Heavy click chemistry reaction mixture (60 ml) was added to the DMSO-treated control sample, and 60 ml of the light reaction mixture was added to the compound-treated sample. The click reaction mixture consisted of TEV tags [10 ml of a 5 mM stock, light (compound-treated) or heavy (DMSO treated)], CuSO 4 (10 ml of a 50 mM stock in water), and tris(benzyltriazolylmethyl) amine (30 ml of a 1.7 mM stock in 4:1 tBuOH/DMSO), to which tris(2-carboxyethyl)phosphine (10 ml of a 50 mM stock) was added. The reaction was performed for 1 hour at room temperature. The light-and heavy-labeled samples were then centrifuged at 16,000g for 5 min at 4°C to harvest the precipitated proteins. The resulting pellets were resuspended in 500 ml of cold methanol by sonication, and the heavy and light samples were combined pairwise. Combined pellets were then washed with cold methanol, after which the pellet was solubilized by sonication in PBS with 1.2% SDS. The samples were heated at 90°C for 5 min and subjected to streptavidin enrichment of probe-labeled proteins, sequential on-bead trypsin and TEV digestion, and liquid chromatography-tandem mass spectrometry, according to the published isoTOP-ABPP protocols (21, 22, 45) .
Peptide and protein identification
RAW Xtractor (version 1.9.9.2; available at http://fields.scripps.edu/ downloads.php) was used to extract the MS2 spectra data from the raw files (MS2 spectra data correspond to the fragments analyzed during the second stage of mass spectrometry). MS2 data were searched against a reverse concatenated, nonredundant variant of the Human UniProt database (release, 2012_11) with the ProLuCID algorithm (publicly available at http://fields.scripps.edu/downloads.php) (46) . Cysteine residues were searched with a static modification for carboxyamidomethylation (+57.02146) and up to one differential modification for either the light or heavy TEV tags (+464.28595 or +470.29976, respectively). Peptides were required to have at least one tryptic terminus and to contain the TEV modification. ProLuCID data were filtered through DTASelect (version 2.0) to achieve a peptide false-positive rate below 1% (47) .
R value calculation and processing
The quantification of heavy/light ratios (isoTOP-ABPP ratios, R values) was performed by in-house CIMAGE software (22) using default parameters (three MS1s per peak and a signal-to-noise threshold of 2.5). Site-specific engagement of electrophilic compounds was assessed by the blockade of IA-alkyne probe labeling. For peptides that showed a ≥95% reduction in MS1 peak area from the compound-treated proteome (light TEV tag) when compared to the DMSO-treated proteome (heavy TEV tag), a maximal ratio of 20 was assigned. Overlapping peptides with the same labeled cysteine [for example, they had the same local sequence around the labeled cysteines but had different charge states, MudPIT (multidimensional protein identification technology) segment numbers, or tryptic termini] were grouped together, and the median ratio from each group was recorded as the R value of the peptide for that run.
Analysis of cysteine conservation
For each human protein containing a DMF-sensitive cysteine, the mouse homolog was identified and the human and mouse sequences were aligned with the align tool on UniProt.
Immunofluorescence analysis of NF-kB translocation
Primary human T cells (500,000 cells per well) were harvested and stimulated as described earlier, with concomitant treatment with DMSO or DMF for 60 min. Cells were pelleted at 500g for 3 min at 4°C, and then the cells in each well were resuspended in 50 ml of PBS and added to poly-D-lysine-coated coverslips (12 mm; 354087, Corning BioCoat). Cells were allowed to adhere to the coverslips for 30 to 60 min at 4°C. The coverslips were then transferred to a six-well plate and fixed with 4% PFA (157-4-100, Electron Microscopy Sciences) at room temperature for 10 min. After washing three times with PBS, the cells were permeabilized with 0.1% Triton X-100 in PBS at room temperature for 10 min. Cells were washed three times with PBS, and then the coverslips were placed cell-side-up on Parafilm. Blocking buffer (150 ml; 2% bovine serum albumin in PBS) was added to each coverslip, and the slides were blocked for 30 min at room temperature. The blocking buffer was aspirated, and the coverslips were placed facedown in 40 ml of antibody buffer (anti-human p65 antibody; 1:500 dilution in blocking buffer; Fivephoton Biochemicals) and incubated overnight at 4°C in a wet chamber. The coverslips were washed three times with PBS and then incubated with 150 ml of secondary antibody (Alexa Fluor 488-conjugated anti-rabbit antibody; 1:200 dilution in PBS; A21441, Life Technologies) for 2 hours at room temperature. After the cells were washed three times with PBS, 150 ml of Hoechst counter stain (5 mg/ml in PBS) was added, and the coverslips were left at room temperature for 30 to 60 min. The cells were again washed three times with PBS and then stained with Alexa Fluor 555-conjugated phalloidin red (1:20 dilution in PBS; 8953S, Cell Signaling). The coverslips were washed with PBS a final three times and then were transferred to Superfrost Plus slides (12-550-15, Fisherbrand) that were spotted with 10 ml of ProLong Gold Antifade Mountant (P36934, ThermoFisher). The circumference of each coverslip was sealed with clear nail polish (72180, Electron Microscopy Sciences). Images were acquired with a Zeiss 780 laser scanning confocal microscope with a 63× objective (0.3-mm image step size) and the automated stitching module to merge (10% overlap) and generate a three-dimensional, multipaneled mega-image composite. The composite image was gathered as a z-series of at least nine individual image panels that were automerged with ZEN software (Zeiss Inc.). The mega-image composite was projected into a maximum image projection in the ZEN software and then was analyzed with the colocalization module in ZEN and Image-Pro Premier (Media Cybernetics) software. The Mander's correlation coefficients, specifically M1 and M2 between the various combinations of fluorescent labels (Alexa Fluor 555-conjugated phalloidin red versus NF-kB-p65 and Hoechst versus NF-kB-p65), were calculated in ZEN per cell and were displayed as percentages. Each cell was outlined using the region-of-interest module, and the software then calculated the M1 and M2 correlation coefficients between the two fluorophores and tabulated the results. The fluorescent signal dynamic range and threshold cutoff of real signal was defined by multiple background and secondary controls. Correlation coefficient values were compared by the Image-Pro Premier (Media Cybernetics), where images were imported as raw calibrated czi files and analyzed with a similar module in Image-Pro Premier. Similar results were obtained with both platforms. Data represent means ± SEM of two or three biological replicates.
Subcloning and mutagenesis
QuikChange site-directed mutagenesis was performed on a pEF4 His A plasmid containing the complementary DNA encoding full-length human PKCq (encoding amino acid residues 1 to 707, courtesy of A.A. and J.X.). The PKCq insert was excised by digestion with Bam HI and Xho I and then ligated into a pMIG vector (courtesy of A.A. and J.X.).
Generation of retrovirus encoding PKCq and transduction and stimulation of cells
Platinum-E packaging cells were plated in a six-well plate in 2 ml of RPMI 1640 medium containing 10% FBS. After 24 hours, the cells were transfected with empty pMIG vector or the appropriate PKCq-expressing vector DNA (3 mg) with the TransIT-LT1 Transfection Reagent (Mirus Bio). After overnight incubation, the medium was replaced and the cultures were maintained for another 24 hours. Retroviral supernatants were then collected and filtered, supplemented with Polybrene (8 mg/ml), and used to infect CD4 + T cells that had been preactivated for 24 hours with plate-bound monoclonal antibody against CD3 (8 mg/ml) and CD28 (8 mg/ml). After centrifuging the plates for 1.5 to 2 hours at 800g, the supernatants were replaced by fresh RPMI 1640 supplemented with 10% FBS and recombinant IL-2 (100 U/ml). Cells were incubated for another 24 hours at 37°C. The cells were then washed, moved to new plates, and cultured in RPMI 1640 medium containing 10% FBS and recombinant IL-2 (100 U/ml), without stimulation for an additional 2 days before they were restimulated with anti-CD3 antibody alone or together with anti-CD28 antibody.
PKCq immunoprecipitation and Western blotting analysis
Cells were lysed in 1% (w/v) digitonin (D141, Sigma) lysis buffer [20 mM tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA] supplemented with the protease inhibitors aprotinin (10 mg/ml), leupeptin (10 mg/ml), and phenylmethylsulfonyl fluoride (1 mM), and with the phosphatase inhibitors sodium pyrophosphate (5 mM) and Na 3 VO 4 (1 mM). Debris was removed by centrifuging the samples at 15,000g for 5 min. Supernatants were then incubated for 2 hours with 1 mg of anti-CD28 monoclonal antibody, and proteins were immunoprecipitated overnight at 4°C with Protein G-Sepharose beads (GE Healthcare). The immunoprecipitated proteins were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto a polyvinylidene difluoride membrane, and incubated overnight at 4°C with primary antibodies, followed by incubation for 1 hour at room temperature with HRPconjugated secondary antibodies. Signals were visualized by enhanced chemiluminescence (GE Healthcare) and were exposed to an x-ray film. Densitometry analysis was performed with ImageJ software. Antibodies specific for CD28 (C-20) and PKCq (C-19) for Western blotting were obtained from Santa Cruz Biotechnology.
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